The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

HER2/neu Expression and Hormonal Therapy in Early Breast Cancer: Can Muddy Waters Become Clear? Authors: Gianluigi Ferretti, Serena Di Cosimo, Diana Giannarelli, Paolo Carlini, Paola Papaldo, Andrea ...

Small-molecule irreversible tyrosine kinase inhibitors as high potent agents have led to improvements in disease-free and overall survival in patients with HER2-amplified cancer. The approved ...

OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein.

Rates of HER2 expression are examined and trastuzumab is tested in combination with paclitaxel and carboplatin in patients with resistant advanced ovarian cancer.

“The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU ...

Amplification of the human epidermal growth factor receptor 2 (HER2, Erb B2) gene leads to persistent activation of signaling pathways that enhance cell proliferation, resistance to apoptosis signals, ...